AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 212.35B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 6.99B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.48 |
| PE Ratio | 30.58 |
| Forward PE | 18.01 |
| Dividend | 2.40 (1.75%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 1,868,518 |
| Average Volume | 1,938,638 |
| Open | 13,612 |
| Previous Close | 13,694 |
| Day's Range | 13,452 - 13,662 |
| 52-Week Range | 9,574 - 14,206 |
| Beta | 0.17 |
| RSI | 52.90 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
FDA Streamlines Clinical Study Requirements, Impacting AstraZeneca (AZN)
FDA Streamlines Clinical Study Requirements, Impacting AstraZeneca (AZN)
AstraZeneca (AZN) Could Benefit from FDA's Shift to Single Study Approval
AstraZeneca (AZN) Could Benefit from FDA's Shift to Single Study Approval
AstraZeneca (AZN) Set to Showcase Hematology Innovations at ASH 2025
AstraZeneca (AZN) Set to Showcase Hematology Innovations at ASH 2025
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) ...
AstraZeneca Shares Dip 0.7% Amid Patent Cliff Fears, But Pipeline Strength Fuels Long-Term Optimism
Thursday saw AstraZeneca PLC shares decline 0.7% and close at 13,546p as the pharmaceutical giant came to grips with new fears over impending patent expiries, despite the continued growth in revenues ...
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report
The U.K. government is bringing together senior pharmaceutical executives to help chart a new direction for the country's drug-pricing system . Whitehall officials will invite reps from AstraZeneca Pl...
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.
AstraZeneca Hypertension Drug Baxdrostat Wins FDA Priority Review
(RTTNews) - AstraZeneca's (AZN) New Drug Application (NDA) for experimental hypertension drug baxdrostat has been granted Priority Review by the U.S. Food and Drug Administration.
UK Government Partners with AstraZeneca (AZN) for Drug Pricing Strategy
UK Government Partners with AstraZeneca (AZN) for Drug Pricing Strategy
AstraZeneca (AZN) Gains FDA Priority Review for Hypertension Drug
AstraZeneca (AZN) Gains FDA Priority Review for Hypertension Drug
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatmen...
Potential Vaccine Schedule Revisions Could Impact AstraZeneca (AZN)
Potential Vaccine Schedule Revisions Could Impact AstraZeneca (AZN)
Michael Hakes' Past Picks: Aritzia, Airbus & AstraZeneca
Michael Hakes, senior portfolio manager at Murray Wealth Group, discusses his past stock picks and how they're doing in the market today.
BREAKING: Trump strikes major deal with UK on drug pricing
FOX Business White House correspondent Edward Lawrence reports the details of President Donald Trump's pharmaceutical deal with the U.K. on 'Varney & Co.'
U.S.-U.K. Pharmaceutical Pricing Agreement to Benefit AstraZeneca (AZN)
U.S.-U.K. Pharmaceutical Pricing Agreement to Benefit AstraZeneca (AZN)
UK Nears Pharmaceuticals Deal with US Benefiting AstraZeneca (AZN)
UK Nears Pharmaceuticals Deal with US Benefiting AstraZeneca (AZN)
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca Shares Soar 7% as Pharma Giant Unveils Breakthrough Cancer Drug Data
Anglo-Swedish pharmaceutical giant AstraZeneca has made investors jump with record-breaking trial outcomes of its next-generation lung cancer treatment, and its shares shot up by 7% on the London Stoc...
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from ...
AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers
FDA approves AstraZeneca's Imfinzi plus FLOT for ... Full story available on Benzinga.com
AstraZeneca (AZN) Gains U.S. Approval for Imfinzi in Cancer Treatment
AstraZeneca (AZN) Gains U.S. Approval for Imfinzi in Cancer Treatment
Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month
The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its highest‑cost medications, resulting in substantial annual savings on presc...
AstraZeneca Announces Approval Of Imfinzi In The US
(RTTNews) - AstraZeneca (AZN, AZN.L) said its Imfinzi, or durvalumab, in combination with standard-of-care FLOT chemotherapy has been approved in the US for the treatment of adult patients with resect...
AstraZeneca (AZN) Gains FDA Approval for Expanded Use of Imfinzi
AstraZeneca (AZN) Gains FDA Approval for Expanded Use of Imfinzi